MX2012009528A - Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. - Google Patents
Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.Info
- Publication number
- MX2012009528A MX2012009528A MX2012009528A MX2012009528A MX2012009528A MX 2012009528 A MX2012009528 A MX 2012009528A MX 2012009528 A MX2012009528 A MX 2012009528A MX 2012009528 A MX2012009528 A MX 2012009528A MX 2012009528 A MX2012009528 A MX 2012009528A
- Authority
- MX
- Mexico
- Prior art keywords
- arthritis
- disease
- cartilage
- chronic
- injury
- Prior art date
Links
- HKUKNCCRHCMALS-UHFFFAOYSA-N 1-oxo-1,3-thiazol-2-amine Chemical class NC1=NC=CS1=O HKUKNCCRHCMALS-UHFFFAOYSA-N 0.000 title 1
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 title 1
- 108091008559 estrogen-related receptor alpha Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010003246 arthritis Diseases 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 208000025940 Back injury Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de formula (I) (Ver Formula) métodos para preparar estos compuestos, composiciones, intermediarios y derivados de los mismos y para tratar una condición que incluye pero no se limita a espondilitis anquilosante, arteroesclerosis, artritis (tal como artritis reumatoide, artritis infecciosa, artritis infantil, artritis soriática, artritis reactiva), enfermedades relacionadas con los huesos (incluyendo aquellas relacionadas con la formación de los huesos), cáncer de mama (incluyendo aquellos insensibles a la terapia antiestrógenos), trastornos cardiovasculares, enfermedad relacionada con los cartílagos (tal como lesión/pérdida de cartílagos, degeneración de cartílagos, y aquellas relacionadas con la formación de los cartílagos), condrodisplasia, condrosarcoma, lesión crónica de la espalda, bronquitis crónica, enfermedad inflamatoria crónica de las vías respiratorias, enfermedad pulmonar obstructiva crónica, diabetes, trastornos de la homeostasis de energía, gota, pseudogota, trastornos de lípidos, síndrome metabólico, mieloma múltiple, obesidad, osteoartritis, osteogénesis imperfecta, metástasis ósea osteolitica, osteomalacia, osteoporosis, enfermedad de Paget, enfermedad periodontal, polimialgia reumática, síndrome de Reiter, lesión por tensión repetitiva, hiperglucemia, nivel elevado de glucosa en la sangre y resistencia a la insulina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30517710P | 2010-02-17 | 2010-02-17 | |
| PCT/US2011/024999 WO2011103130A1 (en) | 2010-02-17 | 2011-02-16 | Aminothiazolones as estrogen related receptor-alpha modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012009528A true MX2012009528A (es) | 2013-01-14 |
Family
ID=43920677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009528A MX2012009528A (es) | 2010-02-17 | 2011-02-16 | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8426604B2 (es) |
| EP (1) | EP2536716B1 (es) |
| JP (1) | JP2013519729A (es) |
| KR (1) | KR20120133383A (es) |
| CN (1) | CN102869660A (es) |
| AR (1) | AR080206A1 (es) |
| AU (1) | AU2011218268A1 (es) |
| BR (1) | BR112012020604A2 (es) |
| CA (1) | CA2789753A1 (es) |
| MX (1) | MX2012009528A (es) |
| RU (1) | RU2012139459A (es) |
| TW (1) | TW201130831A (es) |
| UY (1) | UY33230A (es) |
| WO (1) | WO2011103130A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013051632A1 (ja) * | 2011-10-04 | 2013-04-11 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
| NZ700872A (en) | 2012-03-26 | 2016-09-30 | Nippon Chemiphar Co | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
| JP6527822B2 (ja) | 2013-09-25 | 2019-06-05 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨 |
| TW201811752A (zh) * | 2016-09-06 | 2018-04-01 | 比利時商健生藥品公司 | 用作升糖素受體拮抗劑之吲唑衍生物 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843975A (en) * | 1995-06-02 | 1998-12-01 | Synthelabo | Oxazolidinone derivatives, their preparation and therapeutical use |
| JP2001506996A (ja) | 1996-12-17 | 2001-05-29 | クアドラント ホールディングス ケンブリッジ リミテッド | メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体 |
| CN101014327A (zh) * | 2004-07-14 | 2007-08-08 | 詹森药业有限公司 | 用于治疗雌激素相关α受体介导的疾病的亚芳基类物质 |
| JP4931824B2 (ja) * | 2004-10-22 | 2012-05-16 | エグゼリクシス， インコーポレイテッド | 薬学的組成物 |
| TW200902506A (en) * | 2007-03-07 | 2009-01-16 | Janssen Pharmaceutica Nv | Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators |
-
2011
- 2011-02-16 CN CN2011800194232A patent/CN102869660A/zh active Pending
- 2011-02-16 JP JP2012553980A patent/JP2013519729A/ja not_active Withdrawn
- 2011-02-16 TW TW100105005A patent/TW201130831A/zh unknown
- 2011-02-16 RU RU2012139459/04A patent/RU2012139459A/ru not_active Application Discontinuation
- 2011-02-16 CA CA2789753A patent/CA2789753A1/en not_active Abandoned
- 2011-02-16 US US13/028,266 patent/US8426604B2/en not_active Expired - Fee Related
- 2011-02-16 KR KR1020127023756A patent/KR20120133383A/ko not_active Withdrawn
- 2011-02-16 WO PCT/US2011/024999 patent/WO2011103130A1/en not_active Ceased
- 2011-02-16 BR BR112012020604A patent/BR112012020604A2/pt not_active IP Right Cessation
- 2011-02-16 MX MX2012009528A patent/MX2012009528A/es not_active Application Discontinuation
- 2011-02-16 EP EP11705404.9A patent/EP2536716B1/en active Active
- 2011-02-16 AU AU2011218268A patent/AU2011218268A1/en not_active Abandoned
- 2011-02-17 UY UY0001033230A patent/UY33230A/es unknown
- 2011-02-17 AR ARP110100487A patent/AR080206A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110200586A1 (en) | 2011-08-18 |
| WO2011103130A8 (en) | 2012-09-13 |
| JP2013519729A (ja) | 2013-05-30 |
| BR112012020604A2 (pt) | 2019-09-24 |
| AR080206A1 (es) | 2012-03-21 |
| CA2789753A1 (en) | 2011-08-25 |
| WO2011103130A1 (en) | 2011-08-25 |
| EP2536716B1 (en) | 2014-05-21 |
| TW201130831A (en) | 2011-09-16 |
| RU2012139459A (ru) | 2014-03-27 |
| KR20120133383A (ko) | 2012-12-10 |
| EP2536716A1 (en) | 2012-12-26 |
| US8426604B2 (en) | 2013-04-23 |
| UY33230A (es) | 2011-08-31 |
| CN102869660A (zh) | 2013-01-09 |
| AU2011218268A1 (en) | 2012-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009520A (es) | Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos. | |
| MX2009009519A (es) | Fenoxitiazolidinodionas n-alquiladas sustituidas como moduladores de receptor- alfa relacionados con estrogeno. | |
| UA98485C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА | |
| MX2012009529A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| MX2012009528A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| AR081221A1 (es) | Anticuerpos anti gdf8 humano | |
| JP2010520306A5 (es) | ||
| JP2012506473A5 (es) | ||
| CN103756610B (zh) | 一种双组份耐黄变环氧树脂胶粘剂及其制备方法 | |
| MY156976A (en) | Adhesive and sealants containing cyclohexane dicarboxylic acid esters | |
| UA112973C2 (uk) | Складноефірні проліки [3-(1-(1h-імідазол-4-іл)етил)-2-метилфеніл]метанолу | |
| NZ628627A (en) | Substituted chroman compounds as calcium sensing receptor modulators | |
| EA201990479A1 (ru) | Сульфонамиды в качестве агонистов gpr40 и gpr120 | |
| CA2715113A1 (en) | 11 beta-hydroxysteroid dehydrogenase inhibitors | |
| Nguyen et al. | Synthesis of the bio-based alternative to Bis-GMA and its application to photo-polymerizable adhesives | |
| UA97975C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α | |
| WO2010007363A3 (en) | Preparation of fluorine-labelled compounds | |
| MY160230A (en) | Thermoplastic stiffening materials | |
| JP2012233153A5 (es) | ||
| CN104926854B (zh) | 一种常压低温水相制备巯丙基三乙氧基硅烷的方法 | |
| JP2017505765A5 (es) | ||
| WO2010079498A3 (en) | Novel polymorph of sorafenib tosylate | |
| JP5753717B2 (ja) | 芳香族スルフィド化合物の製造方法 | |
| CN102898455B (zh) | 一种对甲基苯基二乙氧基甲基硅烷及其制备方法 | |
| JP2016023176A (ja) | 化合物及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |